How do GHRPs release growth hormone?

GHRPs bind the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells, activating a Gq/11 protein cascade that produces IP3 and diacylglycerol. IP3 triggers calcium release from intracellular stores, and this calcium spike drives GH vesicle fusion and secretion. The pathway is distinct from GHRH, which uses cAMP signaling instead.

Why do GHRPs and GHRH work better together?

GHRPs activate the IP3/calcium/PKC pathway through GHS-R1a, while GHRH activates the cAMP/PKA pathway through its own receptor. Because these are parallel, non-competing signaling cascades in the same cell, combined administration produces synergistic GH release greater than either agent alone. GHRPs also increase hypothalamic GHRH secretion, adding an indirect amplification.

Is the ghrelin receptor the same as the GHRP receptor?

Yes. The GHS-R1a receptor was identified through GHRP pharmacology decades before its endogenous ligand (ghrelin) was discovered in 1999. GHRPs are synthetic ghrelin receptor agonists. This shared receptor explains why GHRPs produce ghrelin-like effects including appetite stimulation and GH release.

Why does GHRP-6 make you hungry but ipamorelin does not?

Both activate GHS-R1a, but they differ in signaling bias and off-target effects. GHRP-6 strongly activates appetite circuits, potentially through additional receptor interactions beyond GHS-R1a. Ipamorelin activates GHS-R1a more selectively, producing GH release without stimulating cortisol, ACTH, prolactin, or the same degree of appetite signaling.

What is constitutive activity of the ghrelin receptor?

GHS-R1a signals at approximately 50% of its maximum capacity even without ghrelin or a GHRP bound to it. This "always on" baseline activity contributes to tonic appetite regulation and basal GH secretion. Inverse agonists that suppress this constitutive activity reduce food intake in animal models, confirming its physiological relevance.

GHRPs

How GHRPs Activate the Ghrelin Receptor for GH Release

11 min read|March 22, 2026

GHRPs

GHS-R1a receptor

Growth hormone releasing peptides activate the same 366-amino-acid G protein-coupled receptor that binds ghrelin, the stomach-derived hunger hormone discovered in 1999.

Kojima et al., Nature, 1999

View as image

Growth hormone releasing peptides (GHRPs) were discovered through a pharmacological oddity. In the 1970s and 1980s, researchers found that certain synthetic peptides could trigger growth hormone release from the pituitary through a mechanism completely separate from growth hormone-releasing hormone (GHRH).^[1] The receptor they activated was unknown. It took until 1996 to clone it and until 1999 to identify ghrelin as its natural ligand.^[2] This article traces the signaling cascade from GHRP binding to GH secretion, explaining why these peptides work differently from GHRH and why that difference matters pharmacologically. For the broader comparison of individual GHRPs, see our pillar article on hexarelin, the most potent GHRP.

Key Takeaways

GHRPs bind GHS-R1a, a 366-amino-acid G protein-coupled receptor expressed on pituitary somatotrophs and hypothalamic neurons (Smith et al., 2001)
GHS-R1a activates phospholipase C through Gq/11 proteins, producing IP3-mediated calcium release and protein kinase C activation, distinct from GHRH's cAMP pathway (Wu et al., 1996)
Ghrelin, discovered in 1999 as a stomach-derived peptide, turned out to be the endogenous ligand for the same receptor GHRPs had been activating for two decades (Kojima et al., 1999)
GHRP-6 and GHRP-2 produce different magnitudes of GH release despite activating the same receptor, with GHRP-2 showing greater GH potency and less appetite stimulation (Fehrentz et al., 2002)
GHS-R1a has high constitutive activity, meaning it signals even without a ligand bound, which affects baseline GH secretion and appetite regulation (Cornejo et al., 2019)
GHRP and GHRH act synergistically when co-administered because they activate parallel, non-competing signaling cascades in the same somatotroph cell (Fuh and Bach, 1998)

The receptor: GHS-R1a

The growth hormone secretagogue receptor type 1a (GHS-R1a) is a seven-transmembrane G protein-coupled receptor (GPCR) encoded by the GHSR gene.^[3] It contains 366 amino acids and is expressed at highest density in two locations: the anterior pituitary (on somatotroph cells that produce GH) and the hypothalamic arcuate nucleus (on neurons that regulate GH-releasing hormone secretion).

GHS-R1a exists in two splice variants. Type 1a is the full-length, functional receptor that mediates GH release. Type 1b is a truncated, non-functional variant with only five transmembrane domains that does not bind GHRPs or ghrelin.^[3] When studies refer to "the ghrelin receptor" or "the GHS receptor," they mean type 1a.

A distinctive feature of GHS-R1a is its high constitutive activity. Unlike most GPCRs, which remain silent without a ligand, GHS-R1a signals at approximately 50% of its maximum capacity even when no agonist is bound.^[4] Cornejo et al.'s 2019 review documented that this basal signaling contributes to tonic regulation of appetite and GH pulsatility. Inverse agonists (compounds that suppress this constitutive activity) reduce food intake in animal models, confirming that the receptor's unstimulated signaling has physiological consequences.

The signaling cascade: from binding to GH release

When a GHRP binds GHS-R1a on a pituitary somatotroph, the receptor activates heterotrimeric Gq/11 proteins. This initiates a cascade distinct from the one triggered by GHRH at its own receptor:^[5]

Step 1: Phospholipase C activation. Gq/11 activates phospholipase C (PLC), which cleaves the membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).

Step 2: Intracellular calcium release. IP3 binds receptors on the endoplasmic reticulum, triggering release of stored calcium into the cytoplasm. This intracellular calcium spike is the primary signal for GH vesicle exocytosis.

Step 3: Protein kinase C activation. DAG, together with the elevated calcium, activates protein kinase C (PKC). PKC phosphorylates downstream targets including components of the MAPK (mitogen-activated protein kinase) signaling cascade.

Step 4: Extracellular calcium influx. The initial IP3-driven calcium release is amplified by opening of voltage-gated calcium channels in the somatotroph membrane. This extracellular calcium entry sustains the secretory response beyond the initial transient.

Step 5: GH vesicle fusion and release. The sustained calcium elevation drives fusion of GH-containing secretory vesicles with the cell membrane, releasing growth hormone into the pericapillary space.

Wu et al.'s 1996 study in ovine and rat somatotrophs confirmed that GHRP-6 and GHRP-2 both operate through this IP3/calcium pathway rather than through cAMP, the second messenger used by GHRH.^[5] The distinction is pharmacologically critical: because GHRPs and GHRH use parallel, non-competing pathways in the same cell, they produce synergistic GH release when co-administered.

Why GHRPs and GHRH are synergistic

GHRH binds its own receptor (GHRH-R) on somatotrophs and activates the Gs-adenylyl cyclase-cAMP-protein kinase A (PKA) pathway. GHRPs bind GHS-R1a and activate the Gq/11-PLC-IP3-calcium-PKC pathway. These two cascades converge on the same endpoint (GH vesicle release) but through independent signaling routes.^[6]

Fuh and Bach described this as "functional somatostatin antagonism" in their 1998 review. GHRPs potentiate the actions of GHRH on GH secretion by amplifying the secretory response beyond what either stimulus achieves alone.^[6] Clinically, this synergy has been exploited in diagnostic GH stimulation tests, where combined GHRP + GHRH administration produces the most robust GH response.

The synergy also operates at the hypothalamic level. GHS-R1a is expressed on arcuate nucleus neurons that produce GHRH. GHRP activation of these neurons increases GHRH secretion into the portal circulation, which then stimulates somatotrophs through the cAMP pathway. This means GHRPs trigger GH release both directly (at the pituitary) and indirectly (by stimulating GHRH neurons in the hypothalamus).^[6]

Ghrelin: the endogenous GHRP

For over two decades, researchers knew GHRPs activated a specific receptor but could not find its natural ligand. In 1999, Kojima and colleagues isolated a 28-amino-acid peptide from rat stomach that bound GHS-R1a with high affinity.^[2] They named it ghrelin (from "ghre," the Proto-Indo-European root meaning "to grow").

Ghrelin has a unique structural requirement: an octanoyl (8-carbon fatty acid) group must be attached to its serine-3 residue by the enzyme GOAT (ghrelin O-acyltransferase) for it to bind and activate GHS-R1a. Des-acyl ghrelin, which lacks this modification and circulates at much higher concentrations, does not activate GHS-R1a or trigger GH release.^[2]

The discovery resolved a decades-old pharmacological mystery: GHRPs had been synthetic mimics of a hormone that had not yet been found. It also revealed that GHRPs are, functionally, ghrelin receptor agonists. This is why activating GHS-R1a produces not just GH release but also appetite stimulation, gastric motility, and reward signaling. These are ghrelin's core functions. For more on ghrelin's appetite effects, see our article on why GHRP-6 makes you ravenous.

Why different GHRPs produce different effects

All GHRPs activate GHS-R1a, but their pharmacological profiles differ. GHRP-6 produces strong appetite stimulation and raises cortisol and ACTH. GHRP-2 produces greater GH release with less appetite stimulation. Hexarelin is the most potent GH releaser but causes cortisol elevation. Ipamorelin releases GH without affecting cortisol, ACTH, or prolactin at any tested dose.^[1]

These differences arise from several mechanisms:

Receptor binding kinetics. Different GHRPs bind GHS-R1a with different affinities and at slightly different binding poses within the receptor pocket. This affects the duration and magnitude of receptor activation.

Biased agonism. GHS-R1a can activate multiple G protein subtypes (Gq/11, Gi/o, G12/13) and recruit beta-arrestins. Different GHRPs may preferentially activate certain intracellular pathways over others, a phenomenon called biased agonism.^[4] A GHRP that strongly activates Gq/11 (calcium/PKC) but weakly activates other pathways would produce GH release with fewer off-target effects.

Off-target receptor interactions. Some GHRPs interact with receptors beyond GHS-R1a. Hexarelin binds CD36, a scavenger receptor involved in fatty acid uptake and cardioprotection. GHRP-6 activates appetite circuits through mechanisms that may not be entirely GHS-R1a-dependent.^[1]

For a direct head-to-head comparison of how GHRP-2 and GHRP-6 differ in practice, see our dedicated article.

Beyond the pituitary: GHS-R1a elsewhere in the body

GHS-R1a expression extends well beyond the pituitary and hypothalamus. The receptor has been identified in the hippocampus (memory), ventral tegmental area (reward), vagal afferent neurons (gut-brain communication), cardiac tissue, immune cells, and pancreatic islets.^[4]

This broad distribution means GHRPs activate far more than GH release:

Appetite regulation: GHS-R1a in the arcuate nucleus and brainstem drives orexigenic (hunger-promoting) signaling. This is why most GHRPs increase food intake, with the notable exception of ipamorelin.

Neuroprotection: GHS-R1a activation in hippocampal and cortical neurons has demonstrated neuroprotective effects in animal models of neurodegeneration. MK-677, the oral GHS-R1a agonist, has been studied in Alzheimer's disease for this reason.

Cardiac effects: Hexarelin's binding to cardiac CD36 receptors (distinct from GHS-R1a) produces cardioprotective effects independent of GH release. This represents a mechanistic pathway unique among GHRPs.

Metabolic effects: GHS-R1a in pancreatic beta cells modulates insulin secretion, and in adipose tissue it influences lipid metabolism. These effects contribute to the complex metabolic profile of GHRPs, including the insulin resistance seen with chronic GHS-R1a activation.

The somatostatin brake

GH release is not determined solely by stimulatory inputs. Somatostatin (also called growth hormone-inhibiting hormone) tonically suppresses GH secretion from somatotrophs. The balance between GHRH/GHRP stimulation and somatostatin inhibition determines the pulsatile GH secretion pattern.^[6]

GHRPs partially overcome somatostatin's inhibitory tone. Fuh and Bach described GHSs as "functional somatostatin antagonists" because they restore GH pulsatility even in states of elevated somatostatin activity (such as aging).^[6] They do not directly block somatostatin receptors. Instead, the IP3/calcium pathway activated by GHRPs can overcome the cAMP-suppressing effects of somatostatin, allowing GH release to proceed despite ongoing inhibitory input.

This property is central to the clinical rationale for GHRPs in aging. Age-related GH decline is driven partly by increased somatostatin tone. GHRPs can restore pulsatile GH secretion to younger patterns by counteracting this elevated somatostatin activity. For the safety implications of this approach, see our article on growth hormone secretagogue risk profiles.

The Bottom Line

GHRPs activate the ghrelin receptor (GHS-R1a) through a Gq/11-PLC-IP3-calcium cascade that is mechanistically distinct from GHRH's cAMP pathway. This parallel signaling explains the synergistic GH release observed when GHRPs and GHRH are co-administered. The receptor's discovery preceded the identification of its endogenous ligand, ghrelin, by over two decades. Different GHRPs produce different pharmacological profiles despite activating the same receptor, likely through biased agonism and off-target receptor interactions. GHS-R1a's broad tissue distribution means GHRP effects extend well beyond GH release to appetite, neuroprotection, cardiac function, and metabolic regulation.